Journal Article – Tirzepatide Versus Semaglutide for Obesity Treatment
This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted […]
Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms – Pittsburgh Post-Gazette
Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms Pittsburgh Post-Gazette Eli Lilly Sues 4 Telehealth Cos. For Weight Loss Drug Copies Law360 Big Pharma Is Winning the Price War Over Weight Loss Drugs Like Ozempic: Will RFK Jr. and His MAHA Allies Push Back? The New York Sun Navigating The GLP-1 Litigation Landscape Life […]
Can weight-loss drugs like Ozempic help prevent cancer? New study says yes
New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits
Tirzepatide Tops Semaglutide for Weight Loss
In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. Medscape Medical News